# A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin

Study · id `cardio:ct-nct02946541` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02946541](<https://clinicaltrials.gov/study/NCT02946541>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02946541

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT02946541. Randomized; quadruple masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT02946541, source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)
- Start date: 2013-07 (registry gives no type) (ClinicalTrials.gov record NCT02946541, source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT02946541, source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT02946541, source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02946541, source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02946541-2017-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): evogliptin 5mg
- Intervention (Drug): Placebo
- Lead sponsor: Dong-A ST Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Dong-A ST Co., Ltd. (`cardio:org-dong-a-st-co-ltd`)

## Provenance

Content hash: 3bd2d06fedf4c451d6e7139476d051c9ca52353dc73cc55e6962ee0da379e4bc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
